See more : Connected IO Limited (CIO.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Odonate Therapeutics, Inc. (ODT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Odonate Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Chenghe Acquisition Co. (CHEAU) Income Statement Analysis – Financial Results
- Castro Model Ltd. (CAST.TA) Income Statement Analysis – Financial Results
- View Systems, Inc. (VSYM) Income Statement Analysis – Financial Results
- Helix Wind, Corp. (HLXW) Income Statement Analysis – Financial Results
- Argonaut Resources NL (ARE.AX) Income Statement Analysis – Financial Results
Odonate Therapeutics, Inc. (ODT)
About Odonate Therapeutics, Inc.
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 117.04M | 104.03M | 79.95M | 27.90M | 2.62M | 0.00 |
| General & Administrative | 10.39M | 10.90M | 10.82M | 4.84M | 463.00K | 158.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.39M | 10.90M | 10.82M | 4.84M | 463.00K | 158.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -316.00K |
| Operating Expenses | 127.43M | 114.93M | 90.76M | 32.74M | 3.09M | -158.00K |
| Cost & Expenses | 127.43M | 114.93M | 90.76M | 32.74M | 3.09M | 158.00K |
| Interest Income | 0.00 | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 445.00K | 381.00K | 350.00K | 20.00K | 22.82K | 0.00 |
| EBITDA | -125.91M | -111.44M | -88.61M | -32.72M | -3.09M | -158.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -127.43M | -114.93M | -90.76M | -32.74M | -3.09M | -158.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.08M | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -126.35M | -111.83M | -88.96M | -32.74M | -3.09M | -158.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.08M | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
| Net Income | -126.35M | -111.83M | -88.96M | -32.74M | -3.09M | -158.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.85 | -4.05 | -3.64 | -2.31 | -0.11 | -0.01 |
| EPS Diluted | -3.85 | -4.05 | -3.64 | -2.31 | -0.11 | -0.01 |
| Weighted Avg Shares Out | 32.82M | 27.63M | 24.46M | 14.17M | 26.89M | 26.89M |
| Weighted Avg Shares Out (Dil) | 32.82M | 27.63M | 24.46M | 14.17M | 26.89M | 26.89M |
Odonate Therapeutics (ODT) is Oversold: Can It Recover?
Odonate Therapeutics (ODT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Odonate Therapeutics Stock Price Increased 12.14%: Why It Happened
The stock price of Odonate Therapeutics Inc (NASDAQ: ODT) increased by 12.14% unexpectedly. These are some detail about the company you should know about.
Do Options Traders Know Something About Odonate Therapeutics (ODT) Stock We Don't?
Investors need to pay close attention to Odonate Therapeutics (ODT) stock based on the movements in the options market lately.
ODT Stock Price Fell 79.19%: Why It Happened
The stock price of Odonate Therapeutics Inc (NASDAQ: ODT) fell by 79.19% yesterday. This is why it happened.
Odonate Therapeutics stock plummets toward record low after plan to 'wind down' operations
Shares of Odonate Therapeutics Inc. plummeted 79.0% in active afternoon trading Monday, after the pharmaceutical company said it will wind down operations following disappointing data from its cancer treatment. The company said it determined, following feedback from the Food and...
Why Odonate Therapeutics Stock Is Crashing Today
The company's news was so bad that it's going out of business.
Why Odonate, Marker Therapeutics and Dyadic Are Moving Monday
Odonate Therapeutics, Inc. (NASDAQ: ODT), Dyadic International, Inc. (NASDAQ: DYAI) and Marker Therapeutics, Inc. (NASDAQ: MRKR) are among the early biotech movers in Monday's session. Odonate to Shut Shop: Odonate, an oncology-focused pharma company, said it is discontinuing the development...
Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020
NEW YORK--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31,...
Odonate: A Simple Story Of An Oral Taxane
Odonate has only one drug, an oral version of well-known chemo drugs called taxanes. Its Phase 3 trial was solid, but the market may have misunderstood the data.
Odonate Therapeutics: Likely Tesetaxel Approval Means Company Is Undervalued
Odonate is a small biotech attempting to win approval for Tesetaxel, a chemotherapy treatment indicated for treatment of HER2 negative metastatic breast cancer. The company's share price nose dived from $45 in June to $13 in September last year after...
Source: https://incomestatements.info
Category: Stock Reports